Preliminary clinical study of weekly recombinant human endostatin as a hypoxic tumour cell radiosensitiser combined with radiotherapy in the treatment of NSCLC
Clinical and Translational Oncology, 06/12/2012
Jiang XD et al. – Recombinant human endostatin (RHES) combined with radiotherapy within the first week has better short–term therapeutic effects and local control rate, and no severe adverse reactions in treatment of non–small–cell lung cancer (NSCLC). However, it failed to significantly improve the one–year and two–year overall survival rates.
